OBI Pharma, Inc.
OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.
Native name | 台灣浩鼎生技股份有限公司 |
|---|---|
| Type | Public |
| TWSE: 4174(TPEx) | |
| Industry | Pharmaceuticals |
| Founded | 2002 |
| Headquarters | 19F., No.3, Yuanqu st., Nangang, Taipei, Taiwan |
Key people | Michael Chang (Chairman) |
| Website | www.obipharma.com |
History
This company was formerly a subsidiary of Optimer Pharmaceuticals.
On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share.
On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.
On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.